Physician profile
Cesar A Valle
NPI 1023126505
$1,603.05
in general payments reported to CMS, 2019-2025
12 companies · $581 in 2025
The $581 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $56.38 · 2021: $90.55 · 2022: $16.68 · 2023: $397 · 2024: $461 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,439.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $530.26 | 2023-2025 | Wegovy |
| Merck Sharp & Dohme LLC | $250.18 | 2020-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Sanofi Pasteur INC. | $246.48 | 2020-2025 | |
| Kowa Pharmaceuticals America, INC. | $165.75 | 2025 | Zoryve |
| Abbott Laboratories | $159.68 | 2024 | Freestyle Libre 3 |
| Cranial Technologies, INC | $105.61 | 2021-2025 | Doc Band |
| Glaxosmithkline, LLC. | $28.29 | 2020 | |
| Sobi, INC | $28.04 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.40 | 2024 | Jardiance |
| Biomarin Pharmaceutical INC. | $25.10 | 2021 | |
| Apellis Pharmaceuticals, INC. | $22.05 | 2025 | Empaveli |
| Idorsia Pharmaceuticals US INC | $15.21 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cesar Valle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.